Brokerages Set Evolent Health, Inc. (NYSE:EVH) Target Price at $43.00

Evolent Health, Inc. (NYSE:EVH) has been assigned an average rating of “Moderate Buy” from the twelve brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $42.70.

EVH has been the subject of several analyst reports. Canaccord Genuity Group lowered their price target on shares of Evolent Health from $45.00 to $44.00 and set a “buy” rating for the company in a report on Thursday, March 28th. JPMorgan Chase & Co. lowered their price target on shares of Evolent Health from $53.00 to $52.00 and set an “overweight” rating for the company in a report on Friday, March 15th. William Blair restated an “outperform” rating on shares of Evolent Health in a research report on Tuesday, January 9th. Oppenheimer initiated coverage on shares of Evolent Health in a research report on Friday, March 1st. They set an “outperform” rating and a $45.00 price objective for the company. Finally, Citigroup initiated coverage on shares of Evolent Health in a research report on Monday. They set a “buy” rating and a $40.00 price objective for the company.

Institutional Trading of Evolent Health

Institutional investors and hedge funds have recently bought and sold shares of the business. ICA Group Wealth Management LLC purchased a new stake in Evolent Health in the 4th quarter valued at $33,000. Signaturefd LLC raised its position in Evolent Health by 1,470.7% in the 4th quarter. Signaturefd LLC now owns 1,445 shares of the technology company’s stock valued at $48,000 after purchasing an additional 1,353 shares during the last quarter. NBC Securities Inc. purchased a new stake in Evolent Health in the 4th quarter valued at $69,000. Banque Cantonale Vaudoise purchased a new stake in Evolent Health in the 1st quarter valued at $88,000. Finally, Nisa Investment Advisors LLC raised its position in Evolent Health by 389.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,035 shares of the technology company’s stock valued at $137,000 after purchasing an additional 4,006 shares during the last quarter.

Evolent Health Trading Down 2.9 %

NYSE EVH opened at $29.26 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.56. Evolent Health has a 52 week low of $23.33 and a 52 week high of $36.70. The stock has a market capitalization of $3.38 billion, a PE ratio of -23.04 and a beta of 1.53. The firm has a 50 day moving average of $31.93 and a two-hundred day moving average of $30.29.

Evolent Health (NYSE:EVH) last posted its quarterly earnings results on Thursday, February 22nd. The technology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.02 by $0.13. Evolent Health had a negative net margin of 5.76% and a positive return on equity of 6.60%. The company had revenue of $556.06 million during the quarter, compared to analysts’ expectations of $541.87 million. As a group, research analysts expect that Evolent Health will post 0.87 EPS for the current fiscal year.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.